Results 31 to 40 of about 150,672 (260)
OncoImmunology, 2013 These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic profile of other immunotherapeutic approaches-especially vaccines-has not yet been formally clarified.
Yaddanapudi, Kavitha +2 more
openaire +2 more sources
The Cancer Journal, 2011 To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to ...
Ronan J, Kelly, Giuseppe, Giaccone
openaire +2 more sources
The Oncologist, 2002 AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Explain the relationship between the tumor and host immune system.Recognize the mechanisms by which tumor cells escape the immune surveillance.Recognize the potential of vaccines in the treatment and prevention of cancer.Access and take the CME test online and receive ...
openaire +2 more sources
Aging and Cancer Vaccines [PDF]
Critical Reviews in Oncogenesis, 2013 Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by age-related changes of the immune system. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment (TME ...
Claudia, Gravekamp, Dinesh, Chandra
openaire +2 more sources
Scientific Reports, 2018 The human T-cell leukemia virus type 1 (HTLV-1) is highly dependent on cell-to-cell interaction for transmission and productive infection. Cell-to-cell interactions through the virological synapse, biofilm-like structures and cellular conduits have been ...
Maria Omsland +8 more
doaj +1 more source
p30 protein: a critical regulator of HTLV-1 viral latency and host immunity
Retrovirology, 2019 The extraordinarily high prevalence of HTLV-1 subtype C (HTLV-1C) in some isolated indigenous communities in Oceania and the severity of the health conditions associated with the virus impress the great need for basic and translational research to ...
Ramona Moles +8 more
doaj +1 more source
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Journal of Experimental & Clinical Cancer Research, 2022 Emerging evidence has demonstrated that radiotherapy (RT) can not only cause direct damage to cancer cells but also lead to immunogenic cell death (ICD), which involves the activation of host antitumor immune response in tumor immune microenvironment ...
Xuhui Bao, Liyi Xie
doaj +1 more source
Cancer vaccines and immunotherapy [PDF]
British Medical Bulletin, 2002 It is now clear that many human tumour antigens can be recognised by the immune system. These tumour antigens can be classified into several groups including cancer-testis, differentiation, tissue specific, over-expressed, and viral-associated antigens. In many cases, there is a known molecular basis of carcinogenesis which provides the explanation for
Said, Dermime +3 more
openaire +2 more sources
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Molecular Oncology, EarlyView.The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant +7 more
wiley +1 more source